Overview

Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the effect of the addition of inecalcitol to decitabine treatment on overall survival in previously untreated AML patients aged 65 years or more who are randomly assigned to receive decitabine with or without inecalcitol.
Phase:
Phase 2
Details
Lead Sponsor:
Hybrigenics Corporation
Treatments:
Cholecalciferol
Decitabine